## Human EPHA5 Protein


#### Cat. No. EPH-HM1A5

# ϗͶϲϿ·ႮႽ

| Description         |  |
|---------------------|--|
| Source              | Recombinant Human EPHA5 Protein is expressed from HEK293 with His tag at the C-Terminus.   |
|                     | It contains Ala26-Pro573.  |
| Accession           | P54756-1   |
| Molecular<br>Weight | The protein has a predicted MW of 61.9 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on<br>Tris-Bis PAGE result.  |
| Endotoxin           | Less than 1EU per μg by the LAL method.  |
| Purity              | > 95% as determined by Tris-Bis PAGE   |
|                     | > 95% as determined by HPLC  |
| Formulation and S   | torage   |
| Formulation         | Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.   |
| Reconstitution      | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended.<br>Dissolve the lyophilized protein in distilled water.  |
| Storage             | -20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.   |
| Background          |  |
|                     | Ephrin type-A receptor 5 (EphA5) expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer. |
| Assav Data          |  |

### Assay Data

#### **Tris-Bis PAGE**



Human EPHA5 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC

For Research Use Only

